aerovatetx.com (JBIO) - מקדם חוב לטווח ארוך להון

Aerovate Therapeutics Inc (JBIO) develops innovative inhaled therapies for pulmonary vascular diseases. Management has revised its development strategy following clinical setbacks, ensuring transparency in capital allocation. This chart on GURU.Markets reflects the value of 0.00, while the business relies on R&D without current sales, leading to a rapid cash burn of investment resources.

This ratio determines the degree of the company's dependence on debt financing with a maturity of over one year, comparing long-term liabilities to equity to assess financial stability and interest expense risks. By analyzing the long-term debt-to-equity ratio, an investor can evaluate how aggressively Aerovate Therapeutics Inc (JBIO) finances the development of its innovative inhaled drugs for the therapy of pulmonary hypertension.